NasdaqCM - Nasdaq Real Time Price USD

Portage Biotech Inc. (PRTG)

0.2710

+0.0270

(+11.07%)

At close: 4:00 PM EDT

0.2625

-0.01

(-3.14%)

After hours: 6:30 PM EDT

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

-Adenosine clinical development pausedWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. After a review of the Company’s future funding needs for clinical development of its adenosine an

GlobeNewswire 7 days ago
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monet

GlobeNewswire 24 days ago
PRTG: Extending the Runway

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT 3Q:24 Financial and Operational Results Since our initiation in January, Portage Biotech Inc. (NASDAQ:PRTG), has reported its third quarter financial and operational results, and continued to progress the Phase Ia/Ib PORT-6 trial. Eight academic center clinical sites are enrolling patients and the Phase Ia dose escalation

Zacks Small Cap Research last month
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Company focused on adenosine platform clinical developmentWESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and P

GlobeNewswire last month
PRTG: Bridging I-O: Working in Harmony with Checkpoints

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT We are initiating coverage of Portage Biotech Inc. (NASDAQ:PRTG) with a target price of $7.00 per share. This value is based on our estimates for a successful development and commercialization of the small molecule A2A receptor antagonist TT-10 or PORT-6 in advanced solid tumors. The candidate is the subject of Phase Ia/Ib

Zacks Small Cap Research 3 months ago
Portage Biotech Reports Business and Strategic Update

Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company’s comprehensive review of its pipeline in the context of the current capital raising market condi

GlobeNewswire 3 months ago
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual MeetingWESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023. “The Company is focused on developing its two lead clinical programs and maximizing its resources given market condi

GlobeNewswire 4 months ago
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanomaStrong academic interest in the design of the Adenosine 2A(A2A) and Adenosine 2B(A2B) trial for patients with solid tumors with high adenosine receptor expression WESTPORT, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to impro

GlobeNewswire 5 months ago
Portage Biotech Announces $6.0 Million Registered Direct Offering

WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.90 per share (or common stock equ

GlobeNewswire 6 months ago
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY. The Portage management team will participate in one-on-one investor meetings du

GlobeNewswire 6 months ago
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-

GlobeNewswire 7 months ago
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led programUpdated interim data for lead iNKT engager, PORT-2, presented at the 2023 ASCO Annual Meeting showed early evidence of monotherapy activity with minimal toxicityFirst patient dosed in Phase 1a trial of PORT-6 (A2AR antagonist) in select solid tumors WESTPORT, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- Portage

GlobeNewswire 8 months ago
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601 (NCT04969315). The trial is evaluating Portage’s adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal and non-small cell lung canc

GlobeNewswire 9 months ago
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on the favorable safety and tolerability data at all doses tested to date, the Company intends to expand Phase 1 portion of the trial to evaluate higher dose levels; with data anticipated by end of 2023 WESTPORT, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted ther

GlobeNewswire 10 months ago
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Ian Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitorsWESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massach

GlobeNewswire 10 months ago
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. The poster will include updated data from the Company’s Phase 1/2 trial evaluating its lead invariant natural killer T cel

GlobeNewswire 11 months ago

Performance Overview

Return	PRTG	S&P 500
YTD	-85.11%	+4.14%
1-Year	-91.79%	+19.55%
3-Year	-99.00%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Portage Biotech Inc. (PRTG)

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

PRTG: Extending the Runway

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

PRTG: Bridging I-O: Working in Harmony with Checkpoints

Portage Biotech Reports Business and Strategic Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Portage Biotech Announces $6.0 Million Registered Direct Offering

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Performance Overview